Netherlands· NL-b06e65c81d6e

Tivdak 40 mg poeder voor concentraat voor oplossing voor infusie

A tisotumab vedotin product containing tisotumab vedotin, registered in Netherlands by Genmab A/S. The same ATC class is registered in 10 of our 19 countries.

ATC L01FX23

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about tisotumab vedotinAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Tisotumab vedotin is registered in 10 of 19 countries.

Countries holding a registration under ATC L01FX23 (tisotumab vedotin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
6 of them publish a price we can compare per daily dose

Search tisotumab vedotin products by name

Tisotumab vedotin · ATC L01FX23

10 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: TISOTUMAB VEDOTIN
Manufacturer: Genmab A/S
Country: Netherlands (NL)
ATC code: L01FX23
ATC class: Tisotumab vedotin
Defined daily dose: 6.67 mg, P
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/25/1911

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tisotumab vedotin in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tisotumab vedotin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Tivdak
Liechtenstein · Tivdak
Norway · Tivdak

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/fdfffe28-3940-4afc-bddf-9965c5d9c8f5
GET /v1/drugs/fdfffe28-3940-4afc-bddf-9965c5d9c8f5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tivdak-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Tisotumab Vedotin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132887",
  "excipients": [
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "MANNITOL (D-) (E 421)",
    "SACCHAROSE"
  ],
  "substances": [
    "TISOTUMAB VEDOTIN"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/03/28",
  "procedure_number": "EMEA/H/C/005363",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1911",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about tisotumab vedotin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console